KeChow Pharma

Executive Summary

KeChow Pharma is a clinical-stage biopharmaceutical company based in Shanghai's Zhangjiang Pharma Valley, founded in 2014. The company specializes in developing novel small molecule drugs primarily for oncology and free radical-related diseases, leveraging a chemistry-driven drug discovery platform to create best-in-class selective inhibitors. Its lead product, Tolametinib (HL-085/Keluping®), is a MEK inhibitor that has received approval in China, marking a significant commercial milestone. With an employee base of 200-500, KeChow is well-positioned to expand its pipeline and commercial footprint in the Chinese market and potentially beyond. The company's focus on targeted therapies addresses high unmet needs in oncology, and its platform suggests potential for additional candidates in the pipeline, although details remain sparse due to its private status. KeChow's commercial-stage status with a recently approved drug provides a revenue base, but the company faces competition from other MEK inhibitors and the challenges of scaling commercialization in China. Its conviction score is moderate given the early stage of commercial launch and limited public data on pipeline breadth. Upcoming catalysts include label expansion trials for Tolametinib in other cancer types, potential regulatory approvals for combination therapies, and further pipeline disclosures. The company's private nature means catalysts may be less visible, but NMPA approvals and clinical trial milestones in China could be key value drivers.

Upcoming Catalysts (preview)

• Q3 2026Label expansion of Tolametinib for additional oncology indications (e.g., NSCLC or melanoma) in China65% success
• Q4 2026Initiation or interim data readout for a phase 2/3 trial of a next-generation small molecule inhibitor from discovery platform40% success
• TBDStrategic partnership or licensing deal for Tolametinib outside China50% success